 TG Therapeutics is approaching its Prescription Drug User Fee Act PDUFA goal date of December 28, 2022, for ublituximab for the treatment of relapsing forms of multiple sclerosis RMS. It appears that TG will launch ublituximab under the trade name BRIUMVI. 